Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.

ProVerum, an Ireland-based benign prostatic hyperplasia therapy spinout from Trinity College Dublin, secured €30m ($34m) in a series A round yesterday. The round was co-led by Gilde Healthcare Partners and Lightstone Ventures, with commitments from unnamed existing backers. The spinout had raised $4.2m in a seed round involving University Bridge Fund, the spinout-focused venture fund…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.

Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).